Loading…
Artelo Biosciences, Inc. is projected to rise to $1.32 by 2027, a +23% move from its current price of $1.08. ARTL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.03 | $1.08 | $1.14 | +0.02% |
| Jul 13 | $1.01 | $1.08 | $1.16 | +0.04% |
| Jul 14 | $0.99 | $1.08 | $1.18 | +0.06% |
| Jul 15 | $0.9768 | $1.08 | $1.20 | +0.08% |
| Jul 16 | $0.9654 | $1.08 | $1.21 | +0.10% |
| Jul 17 | $0.9552 | $1.08 | $1.22 | +0.12% |
| Jul 18 | $0.946 | $1.08 | $1.24 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.946 | $1.08 | $1.24 | +0.14% |
| Week 2 | $0.8962 | $1.08 | $1.31 | +0.29% |
| Week 3 | $0.8601 | $1.08 | $1.37 | +0.43% |
| Week 4 | $0.831 | $1.09 | $1.42 | +0.57% |
| Week 5 | $0.8063 | $1.09 | $1.47 | +0.71% |
| Week 6 | $0.7847 | $1.09 | $1.51 | +0.86% |
| Week 7 | $0.7654 | $1.09 | $1.55 | +1.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company that develops and commercializes therapeutics that target lipid-signaling pathways in the United States.
Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Artelo Biosciences trades under the symbol ARTL and is currently priced at $1.08 with a market capitalization of $3.76M. Its market rank is 5337.
The technical picture is NEUTRAL, with RSI14 of 30, a 50-day simple moving average of $1.66 and a 200-day simple moving average of $5.34. Near-term support sits at $0.996 and resistance at $1.46. The 30-day range runs from $0.7736 to $1.51, and annualized volatility is listed at 100%.
Forecasts show a path from a 2026 avg of $1.08 toward a 2050 avg of $4.02, with a max forecast up to $9.24 and a series of yearly averages and ROIs illustrating a generally bullish trajectory in later years.
A major floor 33.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.8% below — buyers have tended to step in here.
The nearest ceiling, 35.2% above — a clean break opens room to run.
A major ceiling 875.9% above — clearing it would confirm fresh momentum.
Key ARTL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARTL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.04 | Buy | $1.05 | Buy |
| MA 10 | $1.07 | Buy | $1.08 | Sell |
| MA 20 | $1.17 | Sell | $1.20 | Sell |
| MA 50 | $1.66 | Sell | $1.89 | Sell |
| MA 100 | $3.35 | Sell | $3.29 | Sell |
| MA 200 | $5.34 | Sell | $6.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.73 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -61.46 | Neutral |
| Williams %R (14) | -68.18 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -14.29 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 31.82 | Neutral |
| TRIX (15) | -2.15 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 36.80 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 1.00 | Buy |
| ADX (14) | 39.00 | Sell |
| ATR (14) | 0.06 | Info |
Near-term technicals show a NEUTRAL stance with RSI14 at 30.
The price is below the 50-day SMA of $1.66 and far below the 200-day SMA of $5.34, indicating limited near-term upside relative to longer-term moving averages. The current price of $1.08 sits between a near-term support of $0.996 and resistance of $1.46, within the 30-day range of $0.7736–$1.51.
Overall, the short-term picture is nuanced, with a neutral sentiment and a tendency for range-bound movement around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.996 | $1.08 | $1.43 | 0% | Neutral | |
| $0.9698 | $1.32 | $1.95 | +23% | Bullish | |
| $1.14 | $1.65 | $2.58 | +53% | Bullish | |
| $1.03 | $1.56 | $2.55 | +44% | Bullish | |
| $0.9312 | $1.48 | $2.52 | +37% | Bullish | |
| $0.8559 | $1.41 | $2.49 | +31% | Bullish | |
| $0.7501 | $1.29 | $2.34 | +19% | Neutral | |
| $0.8321 | $1.48 | $2.76 | +37% | Bullish | |
| $0.9172 | $1.69 | $3.24 | +57% | Bullish | |
| $1.02 | $1.95 | $3.82 | +81% | Bullish | |
| $0.8453 | $1.88 | $4.02 | +74% | Bullish | |
| $1.81 | $4.02 | $9.24 | +272% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.996 | $1.08 | $1.27 | +0.00% |
| August 2026 | $0.8522 | $1.03 | $1.29 | -4.65% |
| September 2026 | $0.8985 | $1.10 | $1.41 | +6.84% |
| October 2026 | $0.8768 | $1.09 | $1.42 | -1.28% |
| November 2026 | $0.815 | $1.02 | $1.35 | -6.15% |
| December 2026 | $0.8486 | $1.07 | $1.43 | +5.08% |
Click any year to see its month-by-month ARTL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ARTL could reach as high as $1.43, with a base case around $1.08 and support toward $0.996 — roughly 0% from $1.08. Price action looks broadly range-bound.
Expect ARTL to range from $0.9698 to $1.95 through 2027. The $1.32 average target implies a +23% move from current prices. That is up +23% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ARTL price prediction for 2028 points to an average of $1.65 (low $1.14, high $2.58) — a potential gain of +53% on today's $1.08. Momentum favours further upside here.
In 2029, ARTL is projected to trade between $1.03 and $2.55, averaging $1.56 — a potential gain of +44% from today's $1.08. That is -6% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
Artelo Biosciences, Inc.'s 2030 outlook centres on $1.48, within a $0.9312 to $2.52 range. That is -5% versus the projected 2029 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2031, ARTL could reach as high as $2.49, with a base case around $1.41 and support toward $0.8559 — roughly +31% from $1.08. Buyers look set to stay in control over this stretch.
Expect ARTL to range from $0.7501 to $2.34 through 2032. The $1.29 average target implies a +19% move from current prices. That is -9% versus the projected 2031 average. Price action looks broadly range-bound.
The ARTL price prediction for 2033 points to an average of $1.48 (low $0.8321, high $2.76) — a potential gain of +37% on today's $1.08. Buyers look set to stay in control over this stretch.
In 2034, ARTL is projected to trade between $0.9172 and $3.24, averaging $1.69 — a potential gain of +57% from today's $1.08. That is up +14% on the projected 2033 average. Momentum favours further upside here.
Artelo Biosciences, Inc.'s 2035 outlook centres on $1.95, within a $1.02 to $3.82 range. That is up +15% on the projected 2034 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ARTL could reach as high as $4.02, with a base case around $1.88 and support toward $0.8453 — roughly +74% from $1.08. Momentum favours further upside here.
Expect ARTL to range from $1.81 to $9.24 through 2050. The $4.02 average target implies a +272% move from current prices. That is up +114% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ARTL today (≈ 925.925926 ARTL) could be worth
$3,719.16
+$2,719.16 (+272%) by 2050 · US Dollar
Based on the average projected ARTL price of $4.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARTLwould be worth at today's price.
$1,000 invested in ARTL on Jul 10, 2025 (≈ 11.695906 ARTL) would be worth
$12.63
-$987.37 (-98.7%) today · 0.01× · US Dollar
Based on a ARTL entry price of $85.5 vs. today's $1.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.11 | $972.97 | -2.7% |
| 1 month ago | $1.3 | $830.77 | -16.9% |
| 3 months ago | $5.95 | $181.51 | -81.8% |
| 6 months ago | $4.2 | $257.14 | -74.3% |
| 1 year ago | $85.5 | $12.63 | -98.7% |
| All time (5.0y) ago | $297 | $3.64 | -99.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARTL forecast.
Our base-case forecast reaches $2.20 around 2050.
Implied market cap at $2.20: $7.67M
The multi-year forecast shows a bullish bias in most years beyond 2026, with 2027 avg $1.32 and rising activity through 2029 ($1.56 avg) and 2030 ($1.48 avg). The pattern continues with 2031 ($1.41), 2032 ($1.29), 2033 ($1.48), 2034 ($1.69), 2035 ($1.95), then higher figures into 2040 ($1.88) and 2050 ($4.02).
Key upside milestones include a max forecast of $2.52 in 2030, $3.24 in 2034, and $9.24 in 2050, with ROIs of 36.6 in 2030, 73.9 in 2040, and 271.9 in 2050. Sentiment shifts from NEUTRAL in 2026 and 2032 to BULLISH in subsequent years. These are estimates, not guarantees, and reflect modeled projections under varying conditions.
Tap a question to reveal the answer.
2030 avg $1.48; min $0.9312; max $2.52; ROI 36.6; sentiment BULLISH.
Forecasts show a generally bullish trajectory from 2027 onward, with 2050 avg $4.02 and max $9.24, and ROIs reaching 271.9. These are estimates, not guarantees.
Yes. The max forecast reaches $2.52 in 2030, with higher maxs such as $3.24 in 2034 and $9.24 in 2050.
2026 min $0.996; avg $1.08; max $1.43; sentiment NEUTRAL.
2050 min $1.81; avg $4.02; max $9.24; ROI 271.9; sentiment BULLISH.
Artelo Biosciences, Inc. Community Discussion
0Share your Artelo Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.